ClinicalTrials.gg

Program

atigotatug

Also written as “BMS-986489 (Atigotatug+Nivolumab)” and “BMS-986489”.

Its studies are mostly in Small Cell Lung Carcinoma, led by Bristol-Myers Squibb.

Furthest: phase 3, since Oct 16, 20242 company-led studies, 1 open or runningNext primary completion: Aug 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb21 open or runningphase 3since Oct 16, 2024Oct 16, 2024Aug 17, 2027phase 3 · NCT06646276
  • Named in Bristol-Myers Squibb’s own pipeline as atigotatug, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2024First study: phase 3 study in Small Cell Lung CarcinomaFirst studyNCT06646276 · 530 planned · United States, Argentina, Australia and more
  2. Jan 24, 2025Phase 1 study in Small Cell Lung CarcinomaNCT06799286 · 10 enrolled · China

Ahead

  1. Aug 17, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06646276

TargetBeta

“A fixed-dose combination formulation composed of atigotatug, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the ganglioside fucosyl-GM1, and nivolumab, a human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell surface rec…”NCIt, read by Claude

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06799286Small Cell Lung Carcinoma · China1CompletedSep 9, 202610
NCT06646276Small Cell Lung Carcinoma · United States, Argentina, Australia and more3RecruitingAug 17, 2027530

How it is read

Names in the registry

  • “BMS-986489 (Atigotatug+Nivolumab)”, 1 entry
  • “BMS-986489”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.